By Denny Jacob
Relmada Therapeutics said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance.
The late-stage biotechnology company said an interim analysis of Reliance II conducted by the Independent Data Monitoring Committee determined its assessment of the Phase 3 study. Reliance II was designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder to be used in combination with other approved anti-depressants.
Relmada said no new safety signals were reported.
"Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program," said Chief Executive Sergio Traversa. He added that Relmada will continue to advance a Phase 1 study of REL-P11 as a treatment of metabolic disease.
Trading was halted at 7:25 a.m. ET ahead of its disclosure and has yet to resume trading as of 7:47 a.m. ET.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 04, 2024 07:50 ET (12:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.